FINWIRES · TerminalLIVE
FINWIRES

$TERN

5 stories mentioning TERN

Every FINWIRES story that references TERN, newest first.

Wire

Merck Completes Terns Pharmaceuticals Acquisition

Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%

$MRK$TERN
Research

Update: Mizuho Securities Keeps Terns Pharmaceuticals to Neutral, Price Target to $53

(Updated to keep rating and price target unchanged).Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TERN
Research

Mizuho Securities Downgrades Terns Pharmaceuticals to Neutral From Outperform, Trims Price Target to $53 From $54

Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.

$TERN
Wire

Terns Reports FDA Breakthrough Therapy Label for TERN-701

Terns Pharmaceuticals (TERN) said Monday the US Food and Drug Administration has granted breakthrough therapy designation to TERN-701 for the treatment of certain adult patients with chronic myeloid leukemia.The designation is for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase without the T315I mutation previously treated with two or more tyrosine kinase inhibitors, Terns said.The label is intended to expedite the development and review of potential new medicines for serious conditions or address significant unmet medical needs, it said.Merck agreed in March to buy Terns for $53 per share, or about $6.7 billion.Price: $52.91, Change: $+0.02, Percent Change: +0.03%

$MRK$TERN
Research

Oppenheimer Downgrades Terns Pharmaceuticals to Market Perform From Outperform

Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TERN